It is also planning a late-stage study in lupus nephritis in a bid to match Benlysta, as well as trials in cutaneous lupus erythematosus and myositis.

Artiva Biotherapeutics’ CEO Fred Aslan, MD, identifies data points the company is prioritizing to demonstrate that results from certain trials will translate to similar efficacy across a range of ...

With patients across the ongoing myositis, lupus and systemic sclerosis trials achieving DORIS remission in SLE, complete renal response in LN, and major TIS improvement in dermatomyositis ...